Kobayashi, M.; Numakura, K.; Hatakeyama, S.; Muto, Y.; Sekine, Y.; Sasagawa, H.; Kashima, S.; Yamamoto, R.; Koizumi, A.; Nara, T.;
et al. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes 2022, 13, 1204.
https://doi.org/10.3390/genes13071204
AMA Style
Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T,
et al. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes. 2022; 13(7):1204.
https://doi.org/10.3390/genes13071204
Chicago/Turabian Style
Kobayashi, Mizuki, Kazuyuki Numakura, Shingo Hatakeyama, Yumina Muto, Yuya Sekine, Hajime Sasagawa, Soki Kashima, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara,
and et al. 2022. "Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism" Genes 13, no. 7: 1204.
https://doi.org/10.3390/genes13071204
APA Style
Kobayashi, M., Numakura, K., Hatakeyama, S., Muto, Y., Sekine, Y., Sasagawa, H., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Saito, M., Narita, S., Ohyama, C., & Habuchi, T.
(2022). Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes, 13(7), 1204.
https://doi.org/10.3390/genes13071204
